Effects of LS-2616 administration upon the autoimmune disease of (NZB x NZW) F1 hybrid mice.

Abstract

Autoimmune (NZB X NZW) F1 female hybrid mice were treated with LS-2616, a recently developed substance with immunomodulating properties. Treatment was initiated at the age of 4 months (i.e. at the early stage of the disease) as well as at 7 months of age (i.e. after the development of established lupus-like disease). Control groups treated with cyclophosphamide and physiological saline were also studied. Beneficial therapeutic effects were obtained regardless of when the treatment was initiated and the dose of LS-2616 administered (1 and 8 mg/mouse/week). The effects of LS-2616 on longevity, splenomegaly and glomerulonephritis were pronounced and sometimes comparable to those of cyclophosphamide (1.8 mg/mouse/week). The results obtained suggest that LS-2616 may be useful in the treatment of autoimmune disease in man.

• Authors: A Tarkowski, K Gunnarsson, T Stålhandske
• Journal: Immunology (Immunology) Vol. 59 Issue 4 Pg. 589-94 (Dec 1986) ISSN: 0019-2805 [Print] England
• PMID: 3804379 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Complement C3
• Hydroxyquinolines
• Immunoglobulins
• roquinimex

Topics

• Animals
• Autoimmune Diseases (immunology, mortality, prevention & control)
• Complement C3 (analysis)
• Female
• Hydroxyquinolines (therapeutic use)
• Immunoglobulins (analysis)
• Lupus Erythematosus, Systemic (mortality, prevention & control)
• Lupus Nephritis (immunology, prevention & control)
• Mice